Randomized, multicenter, open-label, Phase 3 study of mirvetuximab soravtansine in combination with bevacizumab versus bevacizumab alone as maintenance therapy for patients with FRα-high recurrent platinum-sensitive epithelial ovarian, fallopian tube, or primary peritoneal cancers who have not progressed after second-line platinumbased chemotherapy plus bevacizumab (GLORIOSA)

HREC Reference Number: 2022/ETH02045
SSA Reference Number: SSA/95106/MonH-2023-370233(v1)
Monash Health Local Reference: RES-23-0000-274X